Positron emission tomography for bone imaging, as an in vivo tracer technique, allows the measurement of the regional concentration of radioactivity proportional to the image pixel values averaged over a region of interest (ROI) in bones. Positron emission tomography is a functional imaging technique that uses [18F]NaF radiotracer to visualise and quantify regional bone metabolism and blood flow. [18F]NaF has been used for imaging bones for the last 60 years. This article focuses on the pharmacokinetics of [18F]NaF in bones, and various semi-quantitative and quantitative methods for quantifying regional bone metabolism using [18F]NaF PET images.
The measurement of regional bone metabolism is critical to understand the pathophysiology of metabolic bone diseases.
The chemically stable anion of Fluorine-18-Fluoride is a bone-seeking radiotracer in skeletal imaging. [18F]NaF has an affinity to deposit at areas where the bone is newly mineralizing. [5] [7] [8] [9] [10] Many studies have [18F]NaF PET to measure bone metabolism at the hip, [3] lumbar spine, and humerus. [11] [18F]NaF is taken-up in an exponential manner representing the equilibration of tracer with the extracellular and cellular fluid spaces with a half-life of 0.4 hours, and with kidneys with a half-life of 2.4 hours. [12] The single passage extraction of [18F]NaF in bone is 100%. [13] After an hour, only 10% of the injected activity remains in the blood. [14]
18F- ions are considered to occupy extracellular fluid spaces because, firstly, they equilibrate with transcellular fluid spaces and secondly, they are not entirely extracellular ions. [15] [16] [17] Fluoride undergoes equilibrium with hydrogen fluoride, which has a high permeability allowing fluoride to cross the plasma blood membrane. [18] The fluoride circulation in red blood cells accounts for 30%. [19] However, it is freely available to the bone surface for uptake because the equilibrium between erythrocytes and plasma is much faster than the capillary transit time. This is supported by studies reporting 100% single-passage extraction of whole-blood 18F- ion by bone [13] and the rapid release of 18F- ions from erythrocytes with a rate constant of 0.3 per second. [20]
[18F]NaF is also taken-up by immature erythrocytes in the bone marrow, [21] which plays a role in fluoride kinetics. [22] The plasma protein binding of [18F]NaF is negligible. [23] [18F]NaF renal clearance is affected by diet [24] and pH level, [25] due to its re-absorption in the nephron, which is mediated by hydrogen fluoride. [26] However, large differences in urine flow rate [19] are avoided for controlled experiments by keeping patents well hydrated. [21]
The exchangeable pool and the size of the metabolically active surfaces in bones determines the amount of tracer accumulated or exchanged [27] with bone extracellular fluid, [28] chemisorption onto hydroxyapatite crystals to form fluorapatite, [14] [29] [9] as shown in Equation-1: [30] [31]
Equation-1
Fluoride ions from the crystalline matrix of bone are released when the bone is remodelled, thus providing a measure of the rate of bone metabolism. [32] [33] [34]
The standardized uptake value (SUV) is defined as tissue concentration (KBq/ml) divided by activity injected normalized for body weight. [35]
The SUV measured from the large ROI smooths out the noise and, therefore, more appropriate in [18F]NaF bone studies as the radiotracer is fairly uniformly taken up throughout the bone. The measurement of SUV is easy, [36] cheap, and quicker to perform, making it more attractive for clinical use. It has been used in diagnosing and assessing the efficacy of therapy. [37] [38] SUV can be measured at a single site, or the whole skeleton using a series of static scans and restricted by the small field-of-view of the PET scanner. [32]
The SUV has emerged as a clinically useful, albeit controversial, semi-quantitative tool in PET analysis. [39] Standardizing imaging protocols and measuring the SUV at the same time post-injection of the radiotracer, is necessary to obtain a correct SUV [40] because imaging before the uptake plateau introduces unpredictable errors of up to 50% with SUVs. [41] Noise, image resolution, and reconstruction do affect the accuracy of SUVs, but correction with phantom can minimize these differences when comparing SUVs for multi-centre clinical trials. [42] [43] SUV may lack sensitivity in measuring response to treatment as it is a simple measure of tracer uptake in bone, which is affected by the tracer uptake in other competing tissues and organs in addition to the target ROI. [44] [45]
The quantification of dynamic PET studies to measure Ki requires the measurement of the skeletal time-activity curves (TAC) from the region of interest (ROI) and the arterial input function (AIF), which can be measured in various different ways. However, the most common is to correct the image-based blood time-activity curves using several venous blood samples taken at discrete time points while the patient is scanned. The calculation of rate constants or Ki requires three steps: [3]
The method was first described by Cunningham & Jones [46] in 1993 for the analysis of dynamic PET data obtained in the brain. It assumes that the tissue impulse response function (IRF) can be described as a combination of many exponentials. Since A tissue TAC can be expressed as a convolution of measured arterial input function with IRF, Cbone(t) can be expressed as:
where, is a convolution operator, Cbone(t) is the bone tissue activity concentration of tracer (in units: MBq/ml) over a period of time t, Cplasma(t) is the plasma concentration of tracer (in units: MBq/ml) over a period of time t, IRF(t) is equal to the sum of exponentials, β values are fixed between 0.0001 sec−1 and 0.1 sec−1 in intervals of 0.0001, n is the number of α components that resulted from the analysis and β1, β2,..., βn corresponds to the respective α1, α2,..., αn components from the resulted spectrum. The values of α are then estimated from the analysis by fitting multi-exponential to the IRF. The intercept of the linear fit to the slow component of this exponential curve is considered the plasma clearance (Ki) to the bone mineral.
The method was first described by Williams et al. in the clinical context. [47] The method was used by numerous other studies. [48] [49] [50] This is perhaps the simplest of all the mathematical methods for the calculation of Ki but the one most sensitive to noise present in the data. A tissue TAC is modelled as a convolution of measured arterial input function with IRF, the estimates for IRF are obtained iteratively to minimise the differences between the left- and right-hand side of the following Equation:
where, is a convolution operator, Cbone(t) is the bone tissue activity concentration of tracer (in units: MBq/ml) over a period of time t, Cplasma(t) is the plasma concentration of tracer (in units: MBq/ml) over a period of time t, and IRF(t) is the impulse response of the system (i.e., a tissue in this case). The Ki is obtained from the IRF in a similar fashion to that obtained for the spectral analysis, as shown in the figure.
The measurement of Ki from dynamic PET scans require tracer kinetic modelling to obtain the model parameters describing the biological processes in bone, as described by Hawkins et al. [22] Since this model has two tissue compartments, it is sometimes called a two-tissue compartmental model. Various different versions of this model exist; however, the most fundamental approach is considered here with two tissue compartments and four tracer-exchange parameters. The whole kinetic modelling process using Hawkins model can be summed up in a single image as seen on the right-hand-side. The following differential equations are solved to obtain the rate constants:
The rate constant K1 (in units: ml/min/ml) describes the unidirectional clearance of fluoride from plasma to the whole of the bone tissue, k2 (in units: min−1) describes the reverse transport of fluoride from the ECF compartment to plasma, k3 and k4 (in units min−1) describe the forward and backward transportation of fluoride from the bone mineral compartment.
Ki represents the net plasma clearance to bone mineral only. Ki is a function of both K1, reflecting bone blood flow, and the fraction of the tracer that undergoes specific binding to the bone mineral k3 / (k2 + k3). Therefore,
Hawkins et al. found that the inclusion of an additional parameter called fractional blood volume (BV), representing the vascular tissue spaces within the ROI, improved the data fitting problem, although this improvement was not statistically significant. [51]
Patlak method [52] is based on the assumption that the backflow of tracer from bone mineral to bone ECF is zero (i.e., k4=0). The calculation of Ki using Patlak method is simpler than using non-linear regression (NLR) fitting the arterial input function and the tissue time-activity curve data to the Hawkins model. The Patlak method can only measure bone plasma clearance (Ki), and cannot measure the individual kinetic parameters, K1, k2, k3, or k4.
The concentration of tracer in tissue region-of-interest can be represented as a sum of concentration in bone ECF and the bone mineral. It can be mathematically represented as
where, within the tissue region-of-interest from the PET image, Cbone(T) is the bone tissue activity concentration of tracer (in units: MBq/ml) at any time T, Cplasma(T) is the plasma concentration of tracer (in units: MBq/ml) at time T, Vo is the fraction of the ROI occupied by the ECF compartment, and is the area under the plasma curve is the net tracer delivery to the tissue region of interest (in units: MBq.Sec/ml) over time T. The Patlak equation is a linear equation of the form
Therefore, linear regression is fitted to the data plotted on Y- and X-axis between 4–60 minutes to obtain m and c values, where m is the slope of the regression line representing Ki and c is the Y-intercept of the regression line representing Vo. [52]
The calculation of Ki using arterial input function, time-activity curve, and Hawkins model was limited to a small skeletal region covered by the narrow field-of-view of the PET scanner while acquiring a dynamic scan. However, Siddique et al. [53] showed in 2012 that it is possible to measure Ki values in bones using static [18F]NaF PET scans. Blake et al. [32] later showed in 2019 that the Ki obtained using the Siddique–Blake method has precision errors of less than 10%. The Siddique–Blake approach is based on the combination of the Patlak method, [52] the semi-population based arterial input function, [54] and the information that Vo does not significantly change post-treatment. This method uses the information that a linear regression line can be plotted using the data from a minimum of two time-points, to obtain m and c as explained in the Patlak method. However, if Vo is known or fixed, only one single static PET image is required to obtain the second time-point to measure m, representing the Ki value. This method should be applied with great caution to other clinical areas where these assumptions may not hold true.
The most fundamental difference between SUV and Ki values is that SUV is a simple measure of uptake, which is normalized to body weight and injected activity. The SUV does not take into consideration the tracer delivery to the local region of interest from where the measurements are obtained, therefore, affected by the physiological process consuming [18F]NaF elsewhere in the body. On the other hand, Ki measures the plasma clearance to bone mineral, taking into account the tracer uptake elsewhere in the body affecting the delivery of tracer to the region of interest from where the measurements are obtained. The difference in the measurement of Ki and SUV in bone tissue using [18F]NaF are explained in more detail by Blake et al. [34]
It is critical to note that most of the methods for calculating Ki require dynamic PET scanning over an hour, except, the Siddique–Blake methods. Dynamic scanning is complicated and costly. However, the calculation of SUV requires a single static PET scan performed approximately 45–60 minutes post-tracer injection at any region imaged within the skeleton.
Many researchers have shown a high correlation between SUV and Ki values at various skeletal sites. [55] [56] [57] However, SUV and Ki methods can contradict for measuring response to treatment. [45] Since SUV has not been validated against the histomorphometry, its usefulness in bone studies measuring response to treatment and disease progression is uncertain.
Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body.
Nuclear medicine, or nucleology, is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear imaging is, in a sense, radiology done inside out, because it records radiation emitted from within the body rather than radiation that is transmitted through the body from external sources like X-ray generators. In addition, nuclear medicine scans differ from radiology, as the emphasis is not on imaging anatomy, but on the function. For such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.
Sodium fluoride (NaF) is an inorganic compound with the formula NaF. It is a colorless or white solid that is readily soluble in water. It is used in trace amounts in the fluoridation of drinking water to prevent tooth decay, and in toothpastes and topical pharmaceuticals for the same purpose. In 2021, it was the 291st most commonly prescribed medication in the United States, with more than 600,000 prescriptions. It is also used in metallurgy and in medical imaging.
A bone scan or bone scintigraphy is a nuclear medicine imaging technique used to help diagnose and assess different bone diseases. These include cancer of the bone or metastasis, location of bone inflammation and fractures, and bone infection (osteomyelitis).
[18F]Fluorodeoxyglucose (INN), or fluorodeoxyglucose F 18, also commonly called fluorodeoxyglucose and abbreviated [18F]FDG, 2-[18F]FDG or FDG, is a radiopharmaceutical, specifically a radiotracer, used in the medical imaging modality positron emission tomography (PET). Chemically, it is 2-deoxy-2-[18F]fluoro-D-glucose, a glucose analog, with the positron-emitting radionuclide fluorine-18 substituted for the normal hydroxyl group at the C-2 position in the glucose molecule.
Fluorine-18 is a fluorine radioisotope which is an important source of positrons. It has a mass of 18.0009380(6) u and its half-life is 109.771(20) minutes. It decays by positron emission 96.7% of the time and electron capture 3.3% of the time. Both modes of decay yield stable oxygen-18.
A Patlak plot is a graphical analysis technique based on the compartment model that uses linear regression to identify and analyze pharmacokinetics of tracers involving irreversible uptake, such as in the case of deoxyglucose. It is used for the evaluation of nuclear medicine imaging data after the injection of a radioopaque or radioactive tracer.
EF5 is a nitroimidazole derivative used in oncology research. Due to its similarity in chemical structure to etanidazole, EF5 binds in cells displaying hypoxia.
Rubidium-82 (82Rb) is a radioactive isotope of rubidium. 82Rb is widely used in myocardial perfusion imaging. This isotope undergoes rapid uptake by myocardiocytes, which makes it a valuable tool for identifying myocardial ischemia in Positron Emission Tomography (PET) imaging. 82Rb is used in the pharmaceutical industry and is marketed as Rubidium-82 chloride under the trade names RUBY-FILL and CardioGen-82.
The standardized uptake value (SUV) is a nuclear medicine term, used in positron emission tomography (PET) as well as in modern calibrated single photon emission tomography (SPECT) imaging for a semiquantitative analysis. Its use is particularly common in the analysis of [18F]fluorodeoxyglucose ([18F]FDG) images of cancer patients. It can also be used with other PET agents especially when no arterial input function is available for more detailed pharmacokinetic modeling. Otherwise measures like the fractional uptake rate (FUR) or parameters from more advanced pharmacokinetic modeling may be preferable.
Brain positron emission tomography is a form of positron emission tomography (PET) that is used to measure brain metabolism and the distribution of exogenous radiolabeled chemical agents throughout the brain. PET measures emissions from radioactively labeled metabolically active chemicals that have been injected into the bloodstream. The emission data from brain PET are computer-processed to produce multi-dimensional images of the distribution of the chemicals throughout the brain.
Mefway is a serotonin 5-HT1A receptor antagonist used in medical research, usually in the form of mefway (18F) as a positron emission tomography (PET) radiotracer.
A Logan plot is a graphical analysis technique based on the compartment model that uses linear regression to analyze pharmacokinetics of tracers involving reversible uptake. It is mainly used for the evaluation of nuclear medicine imaging data after the injection of a labeled ligand that binds reversibly to specific receptor or enzyme.
Florbetaben, sold under the brand name Neuraceq, is a diagnostic radiotracer developed for routine clinical application to visualize β-amyloid plaques in the brain. It is a fluorine-18 (18F)-labeled stilbene derivative.
Fluoroethyl-l-tyrosine (18F) commonly known as [18F]FET, is a radiopharmaceutical tracer used in positron emission tomography (PET) imaging. This synthetic amino acid, labeled with the radioactive isotope fluorine-18, is a valuable radiopharmaceutical tracer for used in neuro-oncology for diagnosing, planning treatment, and following up on brain tumors such as gliomas. The tracer's ability to provide detailed metabolic imaging of tumors makes it an essential tool in the clinical management of brain cancer patients. Continued advancements in PET imaging technology and the development of more efficient synthesis methods are expected to further enhance the clinical utility of [18F]FET.
Fluciclovine (18F), also known as anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid, and sold under the brand name Axumin, is a diagnostic agent used for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels.
Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre. He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.
Carbon-11 choline is the basis of medical imaging technologies. Because of its involvement in biologic processes, choline is related to diseases, leading to the development of medical imaging techniques to monitor its concentration. When radiolabeled with 11CH3, choline is a useful a tracer in PET imaging. Carbon-11 is radioactive with a half-life of 20.38 minutes. By monitoring the gamma radiation resulting from the decay of carbon-11, the uptake, distribution, and retention of carbon-11 choline can be monitored.
Arterial input function (AIF), also known as a plasma input function, refers to the concentration of tracer in blood-plasma in an artery measured over time. The oldest record on PubMed shows that AIF was used by Harvey et al. in 1962 to measure the exchange of materials between red blood cells and blood plasma, and by other researchers in 1983 for positron emission tomography (PET) studies. Nowadays, kinetic analysis is performed in various medical imaging techniques, which requires an AIF as one of the inputs to the mathematical model, for example, in dynamic PET imaging, or perfusion CT, or dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
In medical imaging, a time-activity curve is a curve of radioactivity plotted on the y-axis against the time plotted on the x-axis. It shows the concentration of a radiotracer within a region of interest in an image, measured over time from a dynamic scan. Generally, when a time-activity curve is obtained within a tissue, it is called as a tissue time-activity curve, which represents the concentration of tracer within a region of interest inside a tissue over time.
{{cite book}}
: CS1 maint: multiple names: authors list (link)